Barclays downgraded Moderna (NASDAQ:MRNA) to Equal Weight from Overweight in a note Tuesday, citing policy risks, a lack of major clinical catalysts, and macroeconomic uncertainties that limit the ...
Investor's Business Daily on MSN12h
Is Moderna Stock A Buy As Its CEO Fends Off RFK Jr. Concerns?Moderna stock reversed losses on its fourth-quarter report after CEO Stephane Bancel deflected concerns over RFK Jr. Is MRNA stock a buy?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback